Santhera Names Oliveira CEO as Eklund Exits After Rare Disease Turnaround
Event summary
- Orlando Oliveira appointed CEO of Santhera, effective July 15, 2026, succeeding Dario Eklund after 6.5 years.
- Eklund led Santhera's transformation into a commercial-stage rare disease company focused on AGAMREE® (vamorolone).
- AGAMREE received approvals in the U.S. (October 2023), Europe (December 2023), and the UK (January 2024).
- Oliveira brings 25 years of global biopharma experience, including roles at Zenas BioPharma, Mirati Therapeutics, and Amgen.
The big picture
Santhera's leadership change comes after a successful turnaround under Eklund, who repositioned the company around AGAMREE and secured key regulatory approvals. Oliveira's appointment signals a focus on scaling commercial operations globally, aligning with broader industry trends of rare disease specialization and cross-border partnerships. The transition underscores the importance of leadership renewal in maintaining momentum for commercial-stage biopharma companies.
What we're watching
- Commercial Execution
- How Oliveira will leverage his global experience to accelerate AGAMREE's commercial growth.
- Strategic Partnerships
- Whether Santhera can sustain its international expansion through existing licensing deals.
- Leadership Transition
- The pace at which Oliveira integrates into Santhera's culture and operational rhythm.